AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Strong Q3 beat with raised guidance and removal of going-concern doubt, plus finalized CMS payment framework, skew near-term sentiment positive despite a wide guidance-vs-consensus gap.
RCEL reported Q3 EPS of -$0.20 vs -$0.24 consensus and revenue of $26.1M vs $22.35M consensus (53% YoY growth), and raised FY2026 revenue guidance to $92-94M from $86-89M while reaffirming Q4 cash flow breakeven. The beat-and-raise supports positive near-term sentiment, though the new FY range sits well below the $121.2M analyst consensus, which could temper enthusiasm.
AVITA Medical Investor RelationsCMS finalized national physician RVU valuations and a simplified four-code CPT structure for RECELL SCSA procedures effective January 1, 2027, replacing regional MAC valuations and an eight-code system. Management frames this as improving payment predictability and supporting broader RECELL adoption, a positive structural catalyst for the stock.
AVITA Medical Investor RelationsThe Q3 Form 10-Q no longer carries a going-concern qualification after improved operating performance and liquidity, and the company drew the remaining $10M Perceptive Advisors tranche (total borrowings $60M) after hitting the $85M TTM revenue milestone. Removal of the going-concern doubt and strengthened liquidity reduce perceived financial risk near term.
AVITA Medical Investor RelationsPermeaDerm I met its primary endpoint, showing comparable clinical outcomes to allograft with 70% lower product cost and 95.7% less preparation time. Positive data supports the commercial case for PermeaDerm and adds a potential incremental growth driver, a modest positive for sentiment.
AVITA Medical Investor Relations